Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna stock (NASDAQ: MRNA) declined by about 20% over the last week (five trading days) considerably underperforming the broader S&P 500 which was down by about 3% over the same period. There are a couple of recent developments that have hurt Moderna and Covid-19 vaccine stocks in general.

Moderna Stock Dropped 20% Last Week. Is It Worth A Look?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces the launch of global fellowship program for young researchers exploring mRNA medicines.

Moderna Announces the Launch of Global Fellowship Program for Young Researchers Exploring mRNA Medicines

Novavax

One is a market leader. The other has a big catalyst ahead.

Better COVID Stock: Moderna vs. Novavax

Moderna (MRNA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Moderna (MRNA) is Poised to Beat Earnings Estimates Again

The European Medicines Agency (EMA) has authorized a third dose of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine for immunocompromised people. Related Link:   After Pfizer, Now Moderna Touts Data Supporting COVID-19 Booster Dose.

Moderna's COVID-19 Booster Ok'd In Europe For Immunocompromised

Moderna, Inc. (MRNA) Presents at Chardan 5th Annual Genetic Medicines Conference (Transcript)

Shares of Moderna Inc. MRNA, +2.66% gained 1.2% in trading on Tuesday after the company announced that the European Medicines Agency authorized a third dose of its COVID-19 vaccine for people who are severely immunocompromised. The authorization applies to those who are least 12 years old who have waited at least 28 days since getting their second dose of the vaccine.

E.U. authorizes third dose of Moderna's COVID-19 vaccine for the immunocompromised

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces European Medicines Agency authorizes third dose of COVID-19 vaccine for immunocompromised individuals aged 12 years and older.

Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older

BioNTech SE

These vaccine stocks are now cheaper due to investors' reaction to Merck's COVID-19 pill data.

Does the Sell-Off of BioNTech and Moderna Stocks Present a Buying Opportunity?

The Public Health Agency of Canada said on Friday evening Moderna Inc.'s (NASDAQ:MRNA) covid-19 vaccine triggered a higher rate of heart inflammations after administering the second dose. The agency also said Pfizer Inc. (NYSE:PFE) and BionTech's covid vaccine had fewer cases of heart inflammation.

Should you sell Moderna stock as shares plunge amid covid vaccine side effects

Moderna Inc (NASDAQ: MRNA) stock is trading at its lowest level since late July. This once high-flying stock that notched up stratospheric gains from its COVID-19 program has lost altitude.

Moderna Shares Linger At 2-Month Lows: What's Next For The COVID-19 Vaccine Company

Shares of Moderna Inc (NASDAQ: MRNA) are down more than 15% since Thursday when Merck said its oral COVID-19 pill reduces the risk of hospitalization and death by 50%. But Short Hills Capital Partners' Stephen Weiss is convinced the sell-off is only transitory.

Moderna price forecast: Stephen Weiss sees upside

Investors appear to still be worried about Merck's COVID-19 pill.

Why Moderna Stock Is Sliding Again Today

David Green was back live trading on Benzinga TV on Monday morning. Here's a recap of what he traded and discussed.

How David Green Traded Moderna For A Big Profit On Monday Morning

There's no need to abandon MRNA stock now as Moderna remains an aggressive pioneer in advancing mRNA therapeutics. The post Accept Volatility in Moderna As It Should Prevail in Time appeared first on InvestorPlace.

Accept Volatility in Moderna As It Should Prevail in Time

Moderna Inc (NASDAQ: MRNA) is continuing to trade lower Monday amid news surrounding Merck & Co Inc's (NYSE: MRK) oral COVID-19 treatment. Merck, and Ridgeback, on Friday announced its investigational oral antiviral molnupiravir reduced risk of hospitalization or death by about 50% versus the placebo for patients with mild to moderate COVID-19 in Phase 3 interim analysis.

Why Moderna Shares Continue To Fall Today

The stock price of Moderna Inc (NASDAQ: MRNA) fell by over 11% in the previous trading session. This is why it happened.

MRNA Stock Price: Why It Fell Over 11%

Merck

Merck has reported strong data from its MOVe-OUT trial of molnupiravir. Molnupiravir could be an effective and safe treatment option for COVID.

New COVID Drug Boosts Merck While Moderna And BioNTech Suffer

Bitcoin, Ethereum, Novavax and Moderna were our top stock trades for Monday. Now, let's look at how the charts are setting up for next week.

4 Top Stock Trades for Monday: BTC, ETH, NVAX, MRNA

Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the healthcare sector on Friday, sending the drugmaker's stock price soaring while denting high-flying shares of vaccine companies and makers of other coronavirus therapies.

Merck COVID-19 pill success slams Moderna shares, shakes up healthcare sector

Moderna Inc. (NASDAQ:MRNA) shares are trading lower Friday as most COVID-19 related stocks dropped. Merck announced that molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19.

Is Moderna About To Bounce?

CureVac B.V

Vaxart

Today, vaccine stocks are taking a massive hit as investors price in the potential effect of oral medications for Covid-19 on this sector. The post Vaccine Stocks: Why MRNA, VXRT, CVAC and NVAX Stocks Need a Band-Aid Today appeared first on InvestorPlace.

Vaccine Stocks: Why MRNA, VXRT, CVAC and NVAX Stocks Need a Band-Aid Today

Vaccine manufacturer stocks slumped Friday after Merck announced promising results for a Covid-19 oral pill.

Moderna, Novavax Drop Because Good News on Covid Pill Is Bad News for Vaccines

The COVID-19 pandemic proved to be a boon for many biopharma companies that benefited from their foray into the development of vaccines and/or treatments against the novel coronavirus. Shares of most of them reached incredibly high valuations even after discounting for the COVID opportunity.

Why Moderna, Novavax And Other COVID-19 Vaccine Stocks Are Plummeting

Stephane Bancel, Chief Executive Officer at Moderna (NASDAQ:MRNA), made a large insider sell on September 30, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Bancel sold 23,000 shares of Moderna at prices ranging from ($0.00) to $393.44.

News for Moderna Stock (MRNA)